HANMI SCIENCE CO., LTD.

Patent Owner

Watch Compare Add to Portfolio

Stats

Details

Patent Activity in the Last 10 Years

Technologies

Intl Class Technology Matters Rank in Class
 
  
 
A61K PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES 50205
 
  
 
C07K PEPTIDES 29107
 
  
 
C07D HETEROCYCLIC COMPOUNDS 25137
 
  
 
A61P THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS 940
 
  
 
C12N MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF 8159
 
  
 
C07F ACYCLIC, CARBOCYCLIC, OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM, OR TELLURIUM 565
 
  
 
C12P FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE 594
 
  
 
C07H SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS 396
 
  
 
B29B PREPARATION OR PRETREATMENT OF THE MATERIAL TO BE SHAPED; MAKING GRANULES OR PREFORMS; RECOVERY OF PLASTICS OR OTHER CONSTITUENTS OF WASTE MATERIAL CONTAINING PLASTICS 126
 
  
 
C08F MACROMOLECULAR COMPOUNDS OBTAINED BY REACTIONS ONLY INVOLVING CARBON-TO-CARBON UNSATURATED BONDS 1124

Top Patents (by citation)

Upgrade to the Professional Level to View Top Patents for this Owner. Learn More

Recent Publications

Publication # Title Filing Date Pub Date Intl Class
2015/0056,223 PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASEMar 08, 13Feb 26, 15[A61K, C07K]
2014/0357,843 IMMUNOGLOBULIN FC VARIANTSDec 28, 12Dec 04, 14[A61K, C07K]
2014/0296,475 METHOD FOR PREPARING PHYSIOLOGICALLY ACTIVE POLYPEPTIDE COMPLEXNov 02, 12Oct 02, 14[C07K]
2012/0294,829 LIQUID FORMULATIONS FOR LONG-ACTING G-CSF CONJUGATEJan 18, 11Nov 22, 12[A61K]

Recent Patents

Patent # Title Filing Date Issue Date Intl Class
9867777 Liquid formulations for long-acting G-CSF conjugateJan 18, 11Jan 16, 18[A61K, C07K]
9789202 Method for treating cancer using an interferon alpha conjugateSep 05, 12Oct 17, 17[A61K]
9765131 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the sameOct 06, 16Sep 19, 17[A61K, A61P, C07K]
9750820 IgG Fc fragment for a drug carrier and method for the preparation thereofJul 09, 14Sep 05, 17[A61K, C07K]
9731031 Conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereofJun 15, 12Aug 15, 17[A61K, A61P, C07K]
RE46511 Fused pyrimidine derivatives for inhibition of tyrosine kinase activityApr 14, 16Aug 15, 17[A61K, C07F, C07D, A61P]
9694007 Oral complex composition comprising pseudoephedrine and levocetirizineJan 18, 11Jul 04, 17[A61K]
9669105 Liquid formulations of long-acting interferon alpha conjugatesOct 26, 11Jun 06, 17[A61K, C07K]
9636420 Polypeptide complex comprising non-peptidyl polymer having three functional endsJul 23, 09May 02, 17[A61K, C07K]
9597378 Blood coagulation factor VII and VIIa derivatives, conjugates and complexes comprising the same, and use thereofOct 05, 12Mar 21, 17[A61K, C12N, A61P]

View all patents..

Expired/Abandoned/Withdrawn Patents

Patent # Title Status Filing Date Issue/Pub Date Intl Class
9487569 Oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising the sameWithdrawnJun 07, 12Nov 08, 16[A61K, A61P, C07K]
2016/0229,868 NOVEL FUSED PYRIMIDINE DERIVATIVES FOR INHIBITION OF TYROSINE KINASE ACTIVITYAbandonedApr 15, 16Aug 11, 16[C07F, C07D]
8637700 Method for preparing (3S,4S)-4-((R)-2-(benzyloxy)tridecyl)-3-hexyl-2-oxetanone and novel intermediate used thereforExpiredOct 30, 09Jan 28, 14[C07D]
8624026 Method of preparing sitagliptin and intermediates used thereinExpiredOct 19, 10Jan 07, 14[C07D]
8569490 Intermediate and process for preparing entecavir using sameExpiredDec 24, 09Oct 29, 13[C07F, C07D, C07C]
8569491 Method for preparing entecavir and intermediate used thereinExpiredSep 15, 10Oct 29, 13[C07D]
2013/0243,872 PHARMACEUTICAL COMPOSITE FORMULATION COMPRISING HMG-COA REDUCTASE INHIBITOR AND ASPIRINAbandonedDec 14, 11Sep 19, 13[A61K, G01N]
8475840 Sustained release formulation for oral administration of HMG-CoA reductase inhibitor and method for the preparation thereofExpiredApr 08, 05Jul 02, 13[A61K]
2013/0095,090 FACTOR VIIA COMPLEX USING AN IMMUNOGLOBULIN FRAGMENTAbandonedJun 30, 11Apr 18, 13[C12N]
2013/0071,452 PHARMACEUTICAL COMPOSITION COMPRISING AMIDE DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOFAbandonedJun 10, 11Mar 21, 13[A61K]
2013/0028,974 PHARMACEUTICAL FORMULATION IN THE FORM OF BILAYERED TABLETS COMPRISING HMG-COA REDUCTASE INHIBITOR AND IRBESARTANAbandonedMay 13, 11Jan 31, 13[A61K, A61P]
2013/0022,684 ORAL PHARMACEUTICAL COMPOSITION COMPRISING FENOFIBRIC ACID AND AN ALKALIFYING AGENTAbandonedApr 12, 11Jan 24, 13[A61K, B29B]
2012/0321,709 COMPLEX FORMULATION FOR ORAL ADMINISTRATION COMPRISING PROBIOTIC FORMULATION AND 5-HT4 RECEPTOR AGONIST AND METHOD FOR THE PREPARATION THEREOFAbandonedFeb 25, 11Dec 20, 12[A61K, B05D]
2012/0301,549 COMPLEX FORMULATION COMPRISING ASPIRIN COATED WITH BARRIER CONTAINING HYDROPHOBIC ADDITIVE, AND HMG-COA REDUCTASE INHIBITORAbandonedJan 26, 11Nov 29, 12[A61K, A61P]
8263769 Process for preparing voriconazoleExpiredAug 04, 08Sep 11, 12[C07D]
8242288 Method of preparing (6R)-3-hexyl-4-hydroxy-6-undecyl-5, 6-dihydropyran-2-one, and intermediate used in the methodExpiredOct 29, 08Aug 14, 12[C07D]
8097706 Methods for preparing capecitabine and beta-anomer-rich trialkyl carbonate compound used thereinExpiredNov 07, 08Jan 17, 12[C07H, C07G]
2011/0124,888 STYRYLBENZOFURAN DERIVATIVES AS INHIBITORS FOR BETA-AMYLOID FIBRIL FORMATION AND PREPARATION METHOD THEREOFAbandonedJun 12, 09May 26, 11[C07D]
7858761 1-.alpha.-halo-2,2-difluoro-2-deoxy-D-ribofuranose derivatives and process for the preparation thereofExpiredJun 21, 05Dec 28, 10[C07H]
2010/0317,868 METHOD OF PREPARING TAXANE DERIVATIVES AND INTERMEDIATES USED THEREINAbandonedNov 20, 07Dec 16, 10[C07D]

View all patents..

Top Inventors for This Owner

Upgrade to the Professional Level to View Top Inventors for this Owner. Learn More

We are sorry but your current selection exceeds the maximum number of comparisons () for this membership level. Upgrade to our Level for up to -1 comparisons!

We are sorry but your current selection exceeds the maximum number of portfolios (0) for this membership level. Upgrade to our Level for up to -1 portfolios!.